Semaglutide's meteoric rise transforms diabetes and weight-loss treatments

Semaglutide has become one of the most talked-about drugs in recent years. The medication, used in treatments like Ozempic, Wegovy and Rybelsus, helps manage type 2 diabetes and supports weight loss. Its growing popularity has driven high demand—but also brought market challenges for manufacturers like Novo Nordisk. Semaglutide works by stimulating insulin production and belongs to a class of drugs called GLP-1 receptor agonists. It is the key ingredient in three FDA-approved medications: Ozempic and Rybelsus for type 2 diabetes, and Wegovy, the only version specifically approved for weight loss. To get a prescription, patients must meet certain criteria, such as a qualifying BMI for Wegovy or a diabetes diagnosis for the others.

Between 2024 and 2026, demand for these drugs surged in Germany, pushing Novo Nordisk's stock to record highs—reaching $148.23 in June 2024. However, competition from rivals like Eli Lilly and pricing pressures in the US later slowed growth. By early 2026, the company adjusted its sales forecasts downward by 5% to 13%. Once prescribed, semaglutide medications can be bought at local pharmacies or through telehealth services like Sesame Care. Prices vary depending on the brand, dosage, and whether discounts are applied. Ozempic, Wegovy, and Rybelsus remain widely accessible, though costs can differ significantly between providers.

Semaglutide's rise has reshaped treatment options for diabetes and obesity. While competition and pricing shifts have impacted sales forecasts, the drug remains a major player in the pharmaceutical market. Patients continue to access it through prescriptions, pharmacies, and online platforms.